Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17404485 | 0.88 | KDM5A (0.43) | KDM5A | |
| SCHEMBL29303031 | 0.84 | KDM5A (0.41) | KDM5A | |
| SCHEMBL29303756 | 0.83 | KDM5A (0.38) | IRAK4KDM5APOLB | |
| SCHEMBL28549617 | 0.83 | HRH3 (0.42) | KDM5A | |
| SCHEMBL20809468 | 0.80 | TLR8 (0.52) | IRAK4METKDM5A | |
| Hydrochloric Acid SCHEMBL28859567 | 0.79 | TLR8 (0.51) | IRAK4METKDM5A | |
| SCHEMBL15910733 | 0.78 | IRAK4 (0.45) | IRAK4JAK2JAK1TYK2 | |
| SCHEMBL30122249 | 0.78 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL31559923 | 0.78 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL27004828 | 0.78 | IRAK4 (0.44) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | IRAK4 1/4885MET 940/4885KDM5A 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.